Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Pregnancy is associated with a increased risk of developing blood clots. There is nearly a 5
times greater risk of developing a blood clot in pregnancy. Lovenox is a medication that
helps to prevent the body from developing clots. It is safe to use in pregnancy. Previous
studies have demonstrated that despite recommendation of Lovenox, to prevent blood clots, the
majority of patient's (70 to 90%) did not receive adequate levels of Lovenox at times
throughout the day, which likely increases the risk of developing clots. The increase in
blood volume and increase in kidney function that occurs in pregnancy may contribute to the
inadequate levels. Currently the recommendation for pregnant and nonpregnant patients
requiring Lovenox, is to calculate the daily dose of Lovenox and split the dose, giving half
in the morning and the other half in the evening. This research study proposes that due to
changes in the body during pregnancy that the daily Lovenox dosing be split into three times
a day to achieve more consistent levels of Lovenox than twice a day in pregnant women.